Heat-Shock Protein 90 Inhibitors: Will They Ever Succeed as Chemotherapeutics?

References

• Morimoto RI , TissieresA, GeorgopouloisC. The stress response, function of the proteins and perspectives. In : Stress protein in biology and medicine.MorimotoRI, TissieresA, GeorgopoulosC ( Eds). Cold Spring Harbor Laboratory Press, NY, USA, 1–36 (1990).
   Google Scholar
• Anckar J , SistonenL. Regulation of HSF1 in the heat stress response: implications in aging and disease. Annu. Rev. Biochem.80, 1089–1115 (2011).
   PubMed Web of Science ®Google Scholar
• U.S. National Institutes of Health . www.clinicaltrials.gov.
   Google Scholar
• Modi S , SauraC, HendersonCet al. A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer. Breast Cancer Res. Treat.139, 107–113 (2013).
   PubMed Web of Science ®Google Scholar
• Gandhi N , WildAT, ChettiarSTet al. Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells. Cancer Biol. Ther.14, 347–356 (2013).
   PubMed Web of Science ®Google Scholar
• McConnell JR , McAlpineSR. heat-shock proteins 27, 40, and 70 as combinational therapeutic targets. Bioorg. Med. Chem. Lett.23, 1923–1928 (2013).
   PubMed Web of Science ®Google Scholar
• Morimoto RI . Regulation of the heat-shock transcriptional response: cross talk between a family of heat-shock factors, molecular chaperones, and negative regulators. Genes Dev.12, 3788–3796 (1998).
   PubMed Web of Science ®Google Scholar
• Wang Y , McalpineSR. N-terminal and C-terminal modulation of Hsp90 produce dissimilar phenotypes. Chem. Comm. doi:10.1039/C1034CC07284G (2014) ( In Press).
   Web of Science ®Google Scholar
• McConnell JM , AlexanderLD, McAlpineSR. A heat-shock protein inhibitor that modulates immunophilins and regulates hormone receptors. Bioorg. Med. Chem. Lett.24, 661–666 (2014).
   PubMed Web of Science ®Google Scholar
• Koay YC , McConnellJR, WangY, KimSJ, McAlpineSR. Chemically accessible Hsp90 inhibitor that does not induce a heat shock response. ACS Med. Chem. Lett.5, 771–776 (2014).
   PubMed Web of Science ®Google Scholar
• Eskew JD , SadikotT, MoralesPet al. Development and characeterizatrion of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells. Bio. Med. Central Cancer11, 468 (2011).
   Google Scholar
• Kim YSA , LeeS, LeeM-Jet al. Update on Hsp90 inhibitors in clinical trials. Curr. Top. Med. Chem.9, 1479–1492 (2009).
   PubMed Web of Science ®Google Scholar
• Sellers RP , AlexanderLD, JohnsonVAet al. A third generation of Sansalvamide A derivatives: design and synthesis of Hsp90 inhibitors. Bioorg. Med. Chem.18, 6822–6856 (2010).
   PubMed Web of Science ®Google Scholar
• Kusuma BRZ , SundstromT, PetersonLB, DobrowskyRT, BlaggBS. Synthesis and evaluation of novologues as C-Terminal Hsp90 inhibitors with cytoprotective activity against sensory neuron glucotoxicity. J. Med. Chem.55, 5797–5812 (2012).
   PubMed Web of Science ®Google Scholar
• Centenera MM , FitzpatrickAK, TilleyWD, ButlerLM. Hsp90: still a viable target in prostate cancer. Biochim. Biophys. Acta1835 (2), 211–218 (2013).
   PubMed Web of Science ®Google Scholar
• Yamaki H , SuzukiH, ChoiEC, TanakaN. Inhibition of DNA synthesis in murine tumor cells by geldanamycin, an antibiotic of the benzoquinoid ansamycin group. J. Antibiot. (Tokyo)35, 886–892 (1982).
   PubMed Web of Science ®Google Scholar
• Neckers L , WorkmanP. Hsp90 molecular chaperone inhibitors: are we there yet?Clin. Cancer Res.18, 64–76 (2012).
   PubMed Web of Science ®Google Scholar
• Grem JL , MorrisonG, GuoXDet al. Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J. Clin. Oncol.23, 1885–1893 (2005).
   PubMed Web of Science ®Google Scholar
• Ramsey DM , KitsonRRA, LevinJI, MoodyCJ, McAlpineSR. Recent advances in macrocyclic Hsp90 inhibitors. In : Macrocycles in Drug Discovery.LevinJI ( Ed.). RSC Books, London, UK, 37–77 (2014).
   Google Scholar
• Goldman JW , RajuRN, GordonGAet al. A first in human, safety, pharmacokinetics, and clinical activity Phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies. BMC Cancer13, 152–161 (2013).
   PubMed Web of Science ®Google Scholar
• Kamal A , ThaoL, SensintaffarJet al. A high-affinity conformation of Hsp90 confers tumor selectivity on Hsp90 inhibitors. Nature425, 407 (2003).
   PubMed Web of Science ®Google Scholar